Correlation of secreted frizzled related protein-4 adipokin expression and expression of fatty liver changes under the conditions of a chronic experiment

The article highlights the results of a study of a new method for diagnosing non-alcoholic fatty liver disease in a living organism by determining the serum level of the marker Secreted frizzled related protein-4 (SFRP4) with histological confirmation of the results. In a chronic experiment, the parameters of two groups of experimental animals were studied: control and experimental, 15 rats each. The control (reference) group of animals was in the usual feed and drinking mode, the experimental received food with a high content of carbohydrates and fats. The results of biochemical blood tests and autopsy biomaterials on day 180 of the experiment indicated the presence of fatty changes in the liver in the experimental group of animals. The importance of circulating adipokine SFRP4 in the diagnosis of non-alcoholic fatty liver disease (NAFLD) has been confirmed. A histologically confirmed direct correlation of SFRP4 with the degree of liver fibrosis in NAFLD was revealed. The place of SFRP4 in the pathogenesis of non-alcoholic fatty liver damage is explained. It is noted that in case of successful extrapolation of the results of the study on the human body, information will become a successful solution to one of the most pressing problems of modern hepatology.

1. Starostina E. G. Nutritional structure and associated factors in type 2 diabetic patients. Almanac of Clinical Medicine. 2018;46(3):240–253. (In Russ.) doi:10.18786/2072–0505–2018–46–3–240–253

2. Nath P, Singh SP. Nonalcoholic Fatty Liver Disease: Time to Take the Bull by the Horns. Euroasian J. Hepato-Gastroenterol. 2018; 8(1): 47–51. Doi:10.5005/jp-journals-10018–1257.

3. Tarasova L. V., Tsyganova Yu.V., Opalinskaya I. V., Ivanova A. L. Overview of laboratory diagnostic methods used in nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) at the modern stage. Experimental and Clinical Gastroenterology. 2019; 4 (164): 72–77. (In Russ.) doi:10.31146/1682–8658-ecg-164–4–72–77.

4. Tarasova L. V., Tsyganova Yu.V., Opalinskaya I. V., Stepa shina T. E. Pharmacotherapy of non-alcoholic fatty liver disease: updated data. Jeffektivnaja farmakoterapija. – Effective pharmacotherapy. 2020; 1(16): 70–73. (In Russ.). doi:10.33978/2307–3586–2020–16–1–70–73.

5. Long Wang, Jinghui Guo, Jianping Lu. Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females. Oncotarget. 2016; 7(24): 35632–35642.

6. Takahashi Y., Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014; 20(42): 15539–48. doi: 10.3748/wjg.v20.i42.15539.

7. Sakhuja P. Pathology of alcoholic liver disease, can it be diff erentiated from nonalcoholic steatohepatitis? World J Gastroenterol. 2014; 20(44): 16474–9. doi: 10.3748/wjg.v20.i44.16474.

8. Toshikuni N, Tsutsumi M, Arisawa T. Сlinical diff erences between alcoholic liver disease and non-alcoholic fatty liver disease. World J Gastroenterol. 2014; 20 (26): 8393–8406. DOI: 10.3748/wjg.v20.i26.8393.

9. Preis S. R., Massaro J. M., Robins S. J., et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity (Silver Spring). 2010; 11(18): 2191–2198. Doi:10.1038/oby.2010.59.

10. Elpek G. Ö. Cellular and molecular mechanisms in the pathogenesis of liver fi brosis: An update. World J. Gastroenterol. 2014; 23(20): 7260–7276. Doi:10.3748/wjg.v20.i23.7260.

11. Renée van Amerongen, Roel Nusse. Towards an integrated view of Wnt signaling in development. Development. 2009; 136: 3205–3214. Doi:10.1242/ dev.033910.

12. Hörbelt, T., Knebel, B., Fahlbusch, P., Barbosa, D. et al. Th e adipokine sFRP4 induces insulin resistance and lipogenesis in the liver. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. 2019; 10: 2671–2684. Doi:10.1016/j.bbadis.2019.07.008.

13. Bukhari SA, Yasmin A, Zahoor MA, Mustafa G, Sarfraz I, Rasul A. Secreted frizzled- related protein 4 and its implication in obesity and type-2 diabetes. IUBMB Life. 2019; 71(11): 1701–1710. Doi:10.1002/iub.2123.

14. Guan H, Zhang Y, Gao S, Bai L, Zhao S, Cheng XW, Fan J, Liu E. Differential Patterns of Secreted Frizzled- Related Protein 4 (SFRP4) in Adipocyte Diff erentiation: Adipose Depot Specificity. Cell Physiol. Biochem. 2018; 46(5): 2149–2164. Doi:10.1159/000489545.

15. Tarasova L . V., Diomidova V. N., Tsyganova Yu. V. Secreted frizzled- related protein-4 as one of the indicators of diff erential diagnosis of fatty liver diseases. Vestnik SurGU. Medicina. 2019;(1):73–77. (In Russ.)